Special Issue "Antibacterial, Antibiofilm and Anti-virulence Activity Research of both Natural and Synthetic Products"

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 15 March 2021.

Special Issue Editor

Dr. Eliana De Gregorio
Website
Guest Editor
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
Interests: antimicrobial agent; antibiofilm agent; anti-virulence agent; bacterial pathogenesis; bacterial repeat proteins; acinetobacter baumannii; staphylococcus aureus

Special Issue Information

Dear Colleagues,

Antimicrobial resistance is becoming a global public health treat. The excessive use of traditional antibiotics has resulted in the emergence of multidrug resistance of microorganisms. Multidrug-resistant (MDR) species tend to exhibit high levels of resistance to many antibiotic drug classes, causing infections which are difficult to treat with conventional antibiotic therapies. The ability to form well-organized biofilm makes bacteria highly resistant to the available antibiotics. Despite intensive efforts searching for new antimicrobial agents, there are few active candidates, and new anti-infectives that act through different mechanisms of action are needed. A promising alternative strategy to treat infections caused by MDR bacteria is antivirulence therapy, which is based on the development of drugs able to specifically inhibit virulence factors. The aim of this Special Issue is to present a collection of manuscripts that explore newly discovered antibacterial agents as well as their mode of action in bacteria.

Potential topics may include but are not limited to:

  • Discovery and/or molecular mechanisms of novel compounds with bactericidal or bacteriostatic activity
  • Discovery and/or molecular mechanisms of novel compounds with activity against bacterial and/or fungal biofilm
  • Discovery and molecular mechanisms of novel compounds targeting bacterial virulence factors such as quorum sensing, biofilm formation, motility, toxins, and pigments

Dr. Eliana De Gregorio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial agent
  • antibiofilm agent
  • synergy between new antimicrobial products and conventional antibiotics
  • anti-virulence agent
  • mechanism of drug action
  • repurposing of approved drugs as antibacterial agent
  • biofilms
  • virulence factors

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Pharmacological Potential and Chemical Characterization of Bridelia ferruginea Benth.—A Native Tropical African Medicinal Plant
Antibiotics 2021, 10(2), 223; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10020223 - 23 Feb 2021
Abstract
To avail the possible pharmacological actions of Brideliaferruginea Benth., the present investigation was designed to quantitatively analyze the total flavonoid and phenolic contents and assess the various antioxidant and enzyme inhibition properties of leaf and stem bark extracts (ethyl acetate, water and [...] Read more.
To avail the possible pharmacological actions of Brideliaferruginea Benth., the present investigation was designed to quantitatively analyze the total flavonoid and phenolic contents and assess the various antioxidant and enzyme inhibition properties of leaf and stem bark extracts (ethyl acetate, water and methanolic) of B. ferruginea. Anti-proliferative effect was also investigated against human colon cancer cells (HCT116) as well as the antimicrobial potential against multiple bacterial and fungal (yeasts and dermatophytes) strains. The methanolic and water extracts of the stem bark demonstrated the highest phenolic content (193.58 ± 0.98 and 187.84 ± 1.88 mg/g, respectively), while the leaf extracts showed comparatively higher flavonoid contents (24.37–42.31 mg/g). Overall, the methanolic extracts were found to possess the most significant antioxidant potency. Compared to the other extracts, methanolic extracts of the B. ferruginea were revealed to be most potent inhibitors of acetyl- and butyryl-cholinesterases, tyrosinase α-amylase, except α-glucosidase. Only the ethyl acetate extracts were found to inhibit glucosidase. Additionally, the stem bark methanolic extract also showed potent inhibitory activity against E. coli and gram-positive bacteria (MIC (minimum inhibitory concentration): 2.48–62.99 µg/mL), as well as all the tested fungi (MIC: 4.96–62.99 µg/mL). In conclusion, B. ferruginea can be regarded as a promising source of bioactive compounds displaying multifunctional pharmacological activities and thus is a potential candidate for further investigations in the endeavor to develop botanical formulations for pharmaceutical and cosmeceutical industries. Full article
Show Figures

Figure 1

Open AccessArticle
Baicalein Inhibits Streptococcus mutans Biofilms and Dental Caries-Related Virulence Phenotypes
Antibiotics 2021, 10(2), 215; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10020215 - 21 Feb 2021
Abstract
Dental caries, the most common oral disease, is a major public healthcare burden and affects more than three billion people worldwide. The contemporary understanding of the need for a healthy microbiome and the emergence of antimicrobial resistance has resulted in an urgent need [...] Read more.
Dental caries, the most common oral disease, is a major public healthcare burden and affects more than three billion people worldwide. The contemporary understanding of the need for a healthy microbiome and the emergence of antimicrobial resistance has resulted in an urgent need to identify compounds that curb the virulence of pathobionts without microbial killing. Through this study, we have demonstrated for the first time that 5,6,7-trihydroxyflavone (Baicalein) significantly downregulates crucial caries-related virulence phenotypes in Streptococcus mutans. Baicalein significantly inhibited biofilm formation by Streptococcus mutans UA159 (MBIC50 = 200 μM), without significant growth inhibition. Notably, these concentrations of baicalein did not affect the commensal S. gordonii. Strikingly, baicalein significantly reduced cell surface hydrophobicity, autoaggregation and acid production by S. mutans. Mechanistic studies (qRT-PCR) showed downregulation of various genes regulating biofilm formation, surface attachment, quorum sensing, acid production and competence. Finally, we demonstrate the potential translational value of baicalein by reporting synergistic interaction with fluoride against S. mutans biofilms. Full article
Show Figures

Figure 1

Back to TopTop